become a valuable tool to analyze the roles of specific genes in cardiac diseases. The lack of atrial-specific AAV vector has been a major obstacle for studies into the pathogenesis of atrial diseases. Moreover, gene therapy studies for atrial fibrillation would benefit from atrial-specific vectors. Atrial natriuretic factor (ANF) promoter drives gene expression specifically in atrial cardiomyocytes. 
D
iseases of the atria can pose a serious threat to human health. Atrial fibrillation (AF), for example, is the most common sustained cardiac arrhythmia associated with high morbidity and mortality rates. 1 Because current treatment modalities-both pharmacological therapies and cardiac ablation-remain ineffective in about 40% to 50% of AF patients, 2 there is an urgent need for improved therapies. A better understanding of the molecular mechanisms underlying AF is a prerequisite to the development of new therapeutic approaches. Although mouse models have been helpful in this regard, a major limitation remains ventricular dysfunction arising in global or cardiomyocyte-specific overexpression and deletion models. 3 The sarcolipin-Cre mouse model allows for atrial-specific gene manipulation, 4 but this involves labor-intensive and time-consuming crosses. Moreover, the heterozygous sarcolipin-Cre mice are haploinsufficient for sarcolipin and susceptible to pacing-induced AF induction (data not shown).
Adeno-associated virus (AAV) is widely used as a gene transfer vector in biomedical and gene therapy studies. 5 AAV serotype 9 (AAV9) can efficiently transduce cardiac myocytes, among other cell and tissue types. 6 AAV9 can package sequences up to 4.7 kb that may include a tissue-specific promoter that drives gene expression in the transduced cells. 7 Atrial-specific gene delivery could, therefore, be achieved by careful selection of an atrial-specific promoter. Atrial natriuretic factor (ANF), a peptide hormone synthesized and stored in the atria, was originally identified as a major participant in the systemic regulation of extracellular fluid volume and electrolytes. 8 Nppa, the gene encoding ANF, is initially expressed throughout the whole heart at the early stages of development, but its postnatal expression is restricted to the atrial chambers. 9 Here, we developed an atrial-specific gene transfer vector containing a shortened ANF promoter. AAV9 vectors containing a 653 bp segment of the mouse Nppa promoter 10 were used to drive expression of either enhanced GFP (green fluorescent protein) or Cre recombinase. The AAV9-ANF-GFP vector caused highly specific atrial expression of GFP in vivo in mice. Moreover, a single injection of AAV9-ANF-Cre resulted in efficient and highly specific Cre recombination in the atria, for both a fluorescent Cre-dependent reporter, as well as an endogenous gene. Together, these studies demonstrate that AAV9 vectors with the ANF promoter produce efficient, dose-dependent, and atrial-specific gene expression following a single systemic delivery in mice.
Methods
The authors declare that all supporting data including complete vector sequences are available within the article and its Online Data Supplement. Detailed experimental protocols are provided in the Online Data Supplement. All experiments were performed by operators who were blinded to the genotype/experimental group the animal or sample belonged to.
AAV9 Production and Delivery
Detailed plasmid information and sequences are available in the Online Data Supplement. Plasmids will be publicly shared through Addgene on publication.
Animal Studies and In Vivo Vector Delivery
All studies were performed according to protocols approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine conforming to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The membranetargeted tandem dimer Tomato (mT)/membrane-targeted green fluorescent protein (mG) mice were obtained from Jackson Laboratory (Bar Harbor, ME). A transgenic mouse expressing shRNA targeting JPH2 (junctophilin-2) was previously generated.
5 ShJPH2 mice were crossed to transgenic mice expressing Cre recombinase driven by the αMHC promoter (αMHC)-MerCreMer to achieve cardiac-specific knockdown of JPH2. MerCreMer-shJPH2 mice were intraperitoneal injected (30 mg/kg) with daily 100 μL tamoxifen (Sigma-Aldrich Co, St Louis, MO) for 5 consecutive days. Both male and female mice were used and randomly assigned to treatment groups. AAV vectors were injected retro-orbitally into the venous sinus at doses ranging from 5×10 11 to 5×10 12 genome copies (GC)/mouse diluted in 100 μL of saline.
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Confocal Imaging
Sections were imaged using a Zeiss LSM 880 confocal imaging system. Images were collected using a Zeiss Axiocam 503 mono camera. Images were captured with Zen Software.
Atrial Myocyte Ca 2+ Imaging
Detailed methods are provided in the Online Data Supplement.
Western Blot Analysis
Tissues were snap-frozen in liquid nitrogen. Western blotting was performed as detailed in the Online Data Supplement.
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Statistical Analysis
Results are expressed as mean±SEM. Continuous variables were evaluated using SPSS or Prism using an unpaired Student t test or ANOVA, after performing the D'Agostino-Pearson normality test for normal distribution of the data. Categorical variables were evaluated with Fisher exact test. The generalized estimating equation approach was performed by the use of the binomial distribution to study the dichotomous spontaneous SR Ca 2+ release event. For other multiple group comparison, 1-way ANOVA followed by Tukey post-test was used. P<0.05 was considered statistically significant. 
Nonstandard Abbreviations and Acronyms
Novelty and Significance
What Is Known?
• Atrial fibrillation is the most common sustained cardiac arrhythmia associated with high morbidity and mortality rates.
• Adeno-associated viruses (AAV) are widely used as gene transfer vectors in biomedical research and for gene therapy applications.
• To date, no vector exists for atrial-specific gene transfer.
What New Information Does This Article Contribute?
• AAV serotype 9 (AAV9) containing a shortened atrial natriuretic factor (ANF) promoter provided highly specific atrial gene expression in vivo in mice.
• A single injection of AAV9-ANF-Cre resulted in efficient and highly atrial-specific Cre recombinase expression in the atria.
• Atrial-specific gene expression using AAV9-ANF vectors was not associated with extra-atrial transgene expression or off-target phenotypes.
The findings demonstrate that AAV9 vectors containing the shortened ANF promoter can be used to induce atrial-specific transgene expression or gene knockdown following a single systemic delivery in mice. Atrial-specific AAV vectors will facilitate the identification of novel therapeutic targets as well as enable gene therapy approaches for atrial diseases.
Results
AAV9-ANF-GFP Induces Atrial Myocyte-Specific GFP Expression
To assess the specificity and potency of the ANF promoter fragment within an AAV9 vector, we generated an AAV9-ANF-GFP virus for in vivo studies with a GFP reporter gene ( Figure 1A ). GFP expression patterns were compared with those induced by the AAV9-TNT4-GFP vector with a predicted pan-cardiomyocyte specific expression pattern, and AAV9-enCB-GFP for ubiquitous expression. AAV9-ANF-GFP was delivered to adult C57BL/6J mice at 3 different doses (5×10 11 , 1×10 12 , and 5×10
12 GC) by retro-orbital injection. GFP expression in atrial tissue collected after 4 weeks correlated positively with the AAV9 dose ( Figure 1B ). Mice injected with AAV9-ANF-GFP exhibited robust and specific expression of GFP in the atria ( Figure 1B) , without notable GFP in ventricles or other extracardiac tissues (Figure 1C and 1D ; Online Figure I ). Mice treated with AAV9-TNT4-GFP showed GFP expression in both atria and ventricles ( Figure 1C and 1E) . In contrast, AAV9-enCB-GFP produced ubiquitous expression in the entire heart and other tissues ( Figure 1C ; Online Figure I ).
AAV9-ANF-Cre Provides Efficient LoxP Recombination in Atrial Myocytes of mT/mG Mice
To determine whether the ANF promoter fragment within the AAV9 vector could be used for inducible atrial-specific excision of floxed alleles, we generated an AAV9-ANFCre virus for in vivo studies (Figure 2A) . We used mT/mG, a double-fluorescent Cre reporter mouse that expresses mT before Cre-mediated excision and mG after excision ( Figure 2B ). AAV9-ANF-Cre induced highly efficient LoxP recombination in mT/mG mice only within atria, without notable GFP-positive cells in ventricle or other extracardiac tissues ( Figure 2C ; Online Figure II) . To determine the effect of AAV9 dosage on LoxP recombination in mT/mG mice, we treated mice with 3 different doses of AAV9-ANF-Cre: 5×10 11 , 1×10 12 , or 5×10 12 GC/mouse ( Figure 2D ). The number of transduced cardiomyocytes in atria was detected by Credependent GFP expression from the Rosa26 mT/mG allele. AAV dose was positively correlated with the number of the GFPpositive atrial cardiomyocytes ( Figure 2D and 2E) . The data indicate that a systemic dose of 1×10 12 GC injected at the age of 2 to 3 months produces highly efficient Cre recombination in the majority of atrial cardiomyocytes.
ANF expression has been reported in ventricular tissue under pathological conditions such as heart failure. 13 To determine whether pathological conditions induce extra-atrial Cre expression driven by the ANF promoter fragment within the AAV9 vector, we performed transverse aortic constriction on mTmG mice treated with AAV9-ANF-Cre 1×10 12 GC/mouse 1 week before surgery. The ventricular function of these mice was assessed using echocardiography at 6 weeks after transverse aortic constriction, demonstrating a decline in ejection fraction and dilatation of the left ventricle ( Figure 2G ; Online Table I ). Cardiac sections from transverse aortic constriction mice injected with AAV9-ANF-Cre exhibited efficient Cre recombination in the atria, without notable GFP-positive cells in ventricle ( Figure 2F ). Thus, these data demonstrate that the ANF promoter fragment can be used for atrial-specific gene expression even under pathological conditions such as pressure overload.
AAV9-ANF-Cre Mediated Gene Knockdown in Atrial Myocytes of shJPH2 Mice
Next, we tested whether the AAV9-ANF-Cre vector could be used to selectively knockdown a gene within atrial myocytes. AAV9-ANF-Cre was administered to adult transgenic mice overexpressing shJPH2 on Cre-mediated removal of a loxP-flanked STOP cassette ( Figure 3A ). Four weeks after retro-orbital injection of AAV9-ANF-Cre (1×10 12 GC/mouse), a strong reduction of JPH2 protein expression was observed in atrial samples, whereas JPH2 levels were unaltered in ventricular tissue, liver, kidney, spleen, and lung ( Figure 3B and 3C) . In contrast, JPH2 protein levels were reduced in both atrial and ventricular tissues from shJPH2 mice injected with AAV9-TNT4-Cre ( Figure 3D and 3E) and MerCreMer-shJPH2 mice injected with tamoxifen (Online Figure III) . These data demonstrate the utility of AAV9-ANF-Cre for inducible atrial-specific gene knockdown.
AAV9-ANF-Cre Mediated JPH2 Knockdown Caused Abnormal SR Ca 2+ Handling in Atrial Myocytes
Prior studies revealed that JPH2 knockdown in ventricular myocytes led to profound alterations in intracellular Ca 2+ handling. 14 Confocal imaging revealed that atrial myocytes isolated from shJPH2 mice 4 weeks after AAV9-ANF-Cre administration exhibit a reduced amplitude of the Ca 2+ transient at 1-Hz pacing ( Figure 4A and 4B) . The SR Ca 2+ load assessed using a caffeine dump protocol was also significantly reduced because of JPH2 knockdown. To determine whether diastolic Ca 2+ handling was also affected, spontaneous SR Ca release events were measured in atrial myocytes ( Figure 4D ). Knockdown of JPH2 in shJPH2 mice injected with AAV9-ANF-Cre led to a significantly higher Ca 2+ spark frequency (Figure 4E and 4F; Online Table II) . Finally, echocardiography revealed normal ventricular function in these mice, demonstrating that the changes in atrial Ca 2+ handling are not secondary to altered ventricular function (Online Table III ).
Discussion
AAV9 vectors are a commonly used tool for manipulating gene expression in mouse models of cardiac disease, including atrial arrhythmias. 3, 15 Time and tissue-restricted alterations in gene expression can be achieved by combining Cre and loxP elements within mouse alleles and AAV9 vectors. 15 However, it has been challenging to manipulate gene expression specifically in the atria. A sarcolipin-Cre knockin mouse model has been described, which enables gene deletion in atrial myocytes. 4 A limitation of this model is that Cre replaces one endogenous sarcolipin allele, thus rendering the mice haploinsufficient for this gene, which has important functions in the atria. In our hands, the heterozygous sarcolipin-Cre mice exhibit a high incidence of pacing-induced AF (not shown).
In this study, we demonstrated that AAV9 with an Nppa proximal promoter fragment can be used for in vivo gene delivery to atrial myocytes in an efficient and highly specific manner. Mice injected with AAV9-ANF-GFP produced a strong and specific expression in atrial tissue, while both mice injected with AAV-TNT4-GFP and AAV-enCB-GFP showed a more universal expression in the whole heart. Atrial GFP expression levels were dependent on the AAV9 dose. We also demonstrated the utility of this vector for Cre-mediated recombination using the mT/mG reporter mouse. 16 Although the efficiency of Cre recombination may vary between transgenes, our data suggest that a dose of 1×10 12 GC injected at the age of 2 to 3 months allows for a highly efficient atrial-specific recombination. Our study also shows that AAV9-ANF-Cre is can efficiently knockdown an endogenous protein (JPH2) in the atria of adult conditional transgenic mice that overexpress shRNA to silence JPH2 expression. 17 Downregulation of JPH2 in atrial myocytes was associated with phenotypic changes in SR Ca 2+ handling similar to those observed previously in ventricular myocytes from shJPH2 mice crossed with αMHC-mER-Cre-mER mice.
14 A major advantage of our new vector is that genes can be overexpressed or downregulated in a time-restricted way within atrial myocytes only. Moreover, this platform provides the opportunity to study atrial phenotypes without confounding changes in ventricular gene expression or function, which may occur with pan-cardiomyocyte specific vectors.
The Nppa promoter fragment could also be used to develop transgenic mice. 10 However, the ANF promoter is active in both atria and ventricles before birth and is then repressed in the ventricle postnatally. 10 Therefore, such mice would be expected to overexpress the transgene during cardiac development, which might alter atrial or ventricular function. The AAV9-ANF approach in adult mice would be superior to ANF transgenic mice for studies into the role of genes within the atria without confounding ventricular phenotypes. Prior studies revealed that ANF can be reexpressed in ventricular tissue under pathological conditions such as heart failure. 13 Our data, however, demonstrate that the Nppa promoter fragment 
